After two years of legal battles, regulatory pushback, and a record-breaking divestiture, UnitedHealth Group has finally sealed the deal.
On August 14, 2025, the healthcare giant officially closed its $3.3 billion acquisition of Amedisys, one of the United States’ largest home health and hospice providers.
The move folds Amedisys into UnitedHealth’s Optum division and marks a bold play in the fast-growing U.S. home care market. But it didn’t come cheap or easy.
Alongside the promise of better care at home, the deal leaves behind a trail of penalties, compromises, and plenty of critics questioning what this means for patients, caregivers, and the future of healthcare delivery in America.
So, what’s all this really about?
UnitedHealth-Amedisys acquisition: The deal in a nutshell
UnitedHealth first announced its acquisition of Amedisys in June 2023. However, the deal didn’t move forward as expected. After legal struggles for two years, the healthcare giant is now closing this deal at $3.3 billion.
UnitedHealth’s plans with this deal
The acquisition will make Amedisys a part of Optum, UnitedHealth’s health services division. Unlike UnitedHealthcare, which sells insurance, Optum delivers care directly through clinics, pharmacies, data-driven solutions, and now home health.
Bringing Amedisys into this arm of the business strengthens UnitedHealth’s push into value-based care and home-based services.
The promise: Better care at home
At its core, the deal is about cost and comfort. Home-based care can be 50% to 70% cheaper than inpatient treatment.
For patients, it often means avoiding long, stressful hospital stays.
For UnitedHealth, it means scaling up services that keep people healthier at home and potentially reduce expensive readmissions.
That’s why this acquisition grabbed attention across the healthtech landscape. It’s not just about expansion, but about reshaping where and how care is delivered in the U.S.
If UnitedHealth delivers on its vision, this means earlier detection of health issues, fewer hospital readmissions, and less financial strain on patients.
Then followed the lawsuit
What was the main reason regulators tried to block the deal?
In late 2023, the U.S. Department of Justice (DOJ), along with several states, filed suit to halt the merger. Their main concern was that this acquisition would quash competition.
They argued that by merging these two heavyweights, the new company would control the market in various states, which might result in:
- Higher prices for vulnerable patients receiving home health and hospice care.
- Lower wages for nurses and other care workers due to reduced competition for their talent.
- Fewer choices for families who depend on home health and hospice services.
How did the companies settle the lawsuit and get the deal approved?
To push the deal through, UnitedHealth had to agree to the largest outpatient divestiture ever required for a US acquisition.
The healthcare giant sold off 164 facilities across 19 states for $528 million to preserve market competition.
And there was another unusual penalty involved
The DOJ fined Amedisys $1.1 million civil penalty for failing to fully cooperate during the investigation. Regulators said the company had falsely certified it turned over all necessary documents, only to later hand over 2.5 million additional records, including critical internal emails and texts.
It’s a rare civil fine that underscores how aggressively the DOJ was scrutinizing this deal.
The pushback: Critics aren’t convinced
Despite this settlement by the government, several critics and experts still fear the long-term implications of this merger.
A coalition of Democratic lawmakers and advocacy groups has called the settlement a “failure.” They say that selling off some locations does not solve the fundamental problem.
The divestiture doesn’t solve the core problem: market power.
They fear the deal will still give UHG too much market power, potentially leading to:
- Higher prices for patients.
- Less competition, giving consumers fewer choices.
- Lower wages for nurses and caregivers, as a dominant employer, can suppress pay.
What makes critics so sceptical of UHG’s promises?
Critics’ scepticism is rooted in UHG’s track record, which includes ongoing investigations into Medicare fraud, denying insurance claims, and restricting patient hospitalisations to boost profits.
This history makes them wary of promises that patient care will come first.
The bottom line
UnitedHealth is betting billions that this deal will reshape home care for the better. It’ll lower costs, expand access, and create a system that catches problems before they spiral into emergencies.
But critics see another story. A healthcare giant tightening its grip, with patients and caregivers left to pay the price.
The true cost of this deal will be seen in living rooms across America. Whether families truly get affordable, quality care at home, or whether consolidation once again tilts healthcare toward profit over people.
